...
首页> 外文期刊>Urology >Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pT1b or greater in a matched-pair cohort.
【24h】

Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pT1b or greater in a matched-pair cohort.

机译:配对细胞队列中肾细胞癌分期为pT1b或更高的患者,选择保留肾单位和根治性肾切除术的肿瘤学长期预后。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: To analyze the oncologic outcome and overall survival (OS) for patients with renal cell carcinoma (RCC) >4 cm undergoing radical nephrectomy (RN) or elective nephron-sparing surgery (NSS) in a matched-pair cohort. METHODS: From 1988 to 2007, we identified 829 patients in our clinic treated with either RN (n = 641) or open NSS (n = 188) for renal masses >4 cm. After matching the cohort for age, time of surgery, grade, TNM stage, tumor size, and sex and excluding patients with metastases, benign lesions with an imperative indication, and those with missing records, 173 remained for oncologic analysis. OS, cancer-specific survival, and progression-free survival were estimated using the Kaplan-Meier method. The association with death was evaluated with Cox proportional hazards regression analysis. RESULTS: At the last follow-up visit, 39 patients had died of any cause and 134 were alive at a median of 7.0 years. RN and elective NSS had been performed in 100 and 73 patients, respectively. The OS (P = .357), progression-free survival (P = .558), and cancer-specific survival (P = .239) were not significantly different between the elective NSS and RN groups using the Kaplan-Meier method. On univariate and multivariate Cox regression analysis, the type of surgery did not have an effect on OS (hazard ratio 1.35, 95% confidence interval 0.71-2.54, P = .359). CONCLUSIONS: Our results suggest that it is oncologically safe to perform NSS for renal tumors >4 cm, for which the surgical feasibility according to the tumor location, rather than the tumor size, seemed to be the limiting factor.
机译:目的:分析配对配对队列中接受根治性肾切除术(RN)或择期保肾手术(NSS)的肾细胞癌(RCC)> 4 cm的患者的肿瘤学结局和总体生存率(OS)。方法:从1988年至2007年,我们在我们的诊所中确定了829例接受RN(n = 641)或开放NSS(n = 188)治疗的肾脏肿块> 4 cm。在对队列进行年龄,手术时间,等级,TNM分期,肿瘤大小和性别的匹配后,排除转移,良性病变(有必要指征)和记录缺失的患者,尚有173例用于肿瘤分析。使用Kaplan-Meier方法估算OS,癌症特异性生存期和无进展生存期。与死亡的关联通过Cox比例风险回归分析进行评估。结果:在最后一次随访中,有39例因任何原因死亡,134例存活,中位时间为7.0年。分别对100例和73例患者进行了RN和选择性NSS。使用Kaplan-Meier方法的选择性NSS组和RN组之间的OS(P = .357),无进展生存期(P = .558)和癌症特异性生存期(P = .239)没有显着差异。在单因素和多因素Cox回归分析中,手术类型对OS没有影响(危险比1.35,95%置信区间0.71-2.54,P = .359)。结论:我们的结果表明,对于> 4 cm的肾肿瘤,NSS在肿瘤学上是安全的,根据肿瘤的位置而不是肿瘤的大小,手术可行性似乎是限制因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号